Medication Optimisation for Reducing Events in a Private Practice Setting (MORE)

Awenydd

Status: Unknown

Conditions: Pharmacogenetic Analysis to Reduce Events.

Study type: Observational

Funder types: Industry

Identifiers

NCT00653653

AW_SH_08

Details and patient eligibility

About

Using a prospective study design of two three month periods (before and after genotyping) in which the patients will self-monitor their health status and possible medical events it is hypothesized that it will be shown that patients having their medication altered to fit their genetic status and/or having their medication altered because of inherent interaction potential will have less recordable events after genotyping and medical analysis than before.

It is well known that ADRs (recordable adverse events to medication) are responsible for a large number of deaths and hospitalizations. Furthermore it is well recorded that genotyping of individual cytochrome P450 enzymes (2D6, 2C9, 2C19, among others) is directly related to a metabolic phenotype - fast metabolisers, slow metabolisers, intermediate and normal metabolisers. These differing phenotypes have altered metabolism of many medications and in a number of retrospective clinical trails it has been shown that ADRs and effect can be reduced/bettered through genotyping and alteration of medication.

Enrollment: 500 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• older than 18 years
• not demented
• 1 or more documented events in the previous 6 months.
• more than one medication
• multi-morbid

Exclusion criteria

• demented
• life expectancy less than 1 year
• heart attack within the last 6 months
• Marcumar® Therapy

Trial design

500 participants in 1 patient group

Group A

Description:

Recruited patients will be prospectively observed as one cohort with genotyping/medication interaction analysis after 3 months, followed up by a further 3 month observational period.